Literature DB >> 27490855

Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review.

Atilla Arslanoglu1, Adeel R Seyal1, Faezeh Sodagari1, Azize Sahin1, Frank H Miller1, Riad Salem1, Vahid Yaghmai1.   

Abstract

OBJECTIVE: The purpose of this article is to review aspects of guidelines pertinent to radiologists involved in the diagnosis or treatment of hepatocellular carcinoma.
CONCLUSION: Early diagnosis and treatment of hepatocellular carcinoma are important because only 10% of patients meet the criteria for curative therapy at the time of diagnosis. Several organizations have developed guidelines for screening, diagnosis, and treatment of hepatocellular carcinoma. Radiologists play a pivotal role in every aspect of these guidelines.

Entities:  

Keywords:  guidelines; hepatocellular carcinoma; response assessment; staging; surveillance

Mesh:

Substances:

Year:  2016        PMID: 27490855     DOI: 10.2214/AJR.15.15490

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

1.  Glutathione-s-transferase A 4 (GSTA4) suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting AKT pathway.

Authors:  Chang Jun Liu; Jin Hui Yang; Fei Zhou Huang; Wan Pin Nie; Chu Ping Liu; Xian Hai Mao; Xin Min Yin; Xian Bo Shen; Chuang Peng; Mei Fu Chen; Bo Jiang; Xun Yang Liu; Jin Shu Wu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  Two is better than one: combinatorial receptor targeting enhances hepatocellular carcinoma (HCC) therapeutic response.

Authors:  Celia Sequera; Flavio Maina
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

3.  Epidemiology, clinical treatment patterns, and survival of hepatocellular carcinoma in Manitoba.

Authors:  Nikesh Hanumanthappa; Byung Heon Cho; Andrew McKay; David Peretz; Gerald Y Minuk; Pascal Lambert; Maged Nashed
Journal:  Can Liver J       Date:  2020-06-04

4.  Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC).

Authors:  Ricardo Yamada; Beatriz Bassaco; Stephen Bracewell; Kirkpatrick Gillen; Madison Kocher; Heather Collins; Michael Bret Anderson; Marcelo Guimaraes
Journal:  J Gastrointest Oncol       Date:  2019-04

5.  Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?

Authors:  Mustafa Kurucay; Christopher Kloth; Sascha Kaufmann; Konstantin Nikolaou; Hans Bösmüller; Marius Horger; Wolfgang M Thaiss
Journal:  Cancer Imaging       Date:  2017-06-28       Impact factor: 3.909

6.  Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma.

Authors:  Shoubao Gao; Xiaohong Xu; Yue Wang; Wei Zhang; Xingye Wang
Journal:  Mol Med Rep       Date:  2018-07-30       Impact factor: 2.952

Review 7.  Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review.

Authors:  Shamar Young; Andrew J Taylor; Tina Sanghvi
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

8.  Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma.

Authors:  Wali Badar; Thuong Van Ha; Steven Zangan; Rakesh Navuluri; Anjana Pillai; Talia Baker; Osman Ahmed
Journal:  Gastrointest Tumors       Date:  2020-07-28

9.  Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: Application of automated measurements on computed tomography scans.

Authors:  Junta Yamamichi; Yasunori Kawaguchi; Taiga Otsuka; Shunya Nakashita; Hideaki Mizobe; Yuichiro Eguchi; Shinya Kimura
Journal:  JGH Open       Date:  2019-08-02

10.  Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma.

Authors:  Hongmei Jin; Hui Wang; Guanghao Li; Qingshun Hou; Wei Wu; Fuhui Liu
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.